{"id":254,"date":"2026-04-10T05:02:34","date_gmt":"2026-04-10T05:02:34","guid":{"rendered":"https:\/\/www.merckconnect.com\/ohtuvayre\/?page_id=254"},"modified":"2026-08-21T20:08:13","modified_gmt":"2026-08-21T20:08:13","slug":"copd-symptoms-patient-profiles","status":"publish","type":"page","link":"https:\/\/www.merckconnect.com\/ohtuvayre\/copd-symptoms-patient-profiles\/","title":{"rendered":"Patient profiles"},"content":{"rendered":"\n\n
<\/div>\n\n\n\n\n
<\/div>\"\"<\/picture>

Explore OHTUVAYRE\u00ae (ensifentrine) for adult patients with COPD<\/h1>

For patients experiencing persistent COPD symptoms, OHTUVAYRE is a novel non-steroidal therapy that reduces inflammation and increases bronchodilation through selective PDE3 and PDE4 inhibition.1,2<\/sup><\/p>

<\/div>
<\/div><\/div><\/div><\/div>
<\/div>
<\/div><\/div>\n\n\n\n
<\/div>\n\n\n\n\n
\n\n\n\n
<\/div>\n\n\n\n

Do not use OHTUVAYRE to treat acute episodes of bronchospasm.<\/p>\n\n\n\n

<\/div>\n\n\n\n\n
\n
<\/div>\n\n\n\n\n
\n\n
\n

Michael, age 67<\/a> |<\/strong><\/strong><\/p>\n<\/div>\n\n\n\n

\n

Jackie, age 65<\/strong><\/a> |<\/strong><\/strong><\/p>\n<\/div>\n\n\n\n

\n

Eva, age 66<\/a><\/strong><\/strong><\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n<\/div><\/div><\/div>\n\n\n\n
<\/div>\n\n\n\n

Background therapy in ENHANCE-1 and ENHANCE-2 did not include participants on LABA + LAMA or LABA + LAMA + ICS. The efficacy results may not translate to these patient populations.<\/strong><\/p>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\n\n
<\/div>
\"\"\/<\/picture>

<\/p><\/figcaption>

Actor Portrayal<\/div><\/div><\/figure><\/div>\n<\/div>\n\n\n\n
\n\n

Michael,<\/strong> age 67<\/h2><\/div>\n\n\n\n
<\/div>\n\n\n\n

Michael is an electrician, but his COPD symptoms,<\/strong> including persistent dyspnea<\/strong> and chronic productive cough,<\/strong> have started slowing him down. He\u2019s beginning to worry he won\u2019t be able to manage the demands of his work much longer.1<\/sup><\/p>\n\n\n\n

<\/div>\n\n\n\n\n
\"\"\/<\/picture><\/figure><\/div>
\n

Currently on LABA + LAMA + ICS<\/strong><\/p><\/div><\/div>\n<\/div><\/div><\/div><\/div>\n\n\n\n

\"\"\/<\/picture><\/figure><\/div>
\n

Post-bronchodilator FEV1<\/sub> is 48%<\/strong> of predicted<\/p>\n<\/div><\/div><\/div><\/div>\n\n\n\n

\"\"\/<\/picture><\/figure><\/div>
\n

Baseline eosinophil count is 120 cells\/\u03bcL<\/span><\/strong>2<\/sup><\/p>\n<\/div><\/div><\/div><\/div>\n\n\n\n

\"\"\/<\/picture><\/figure><\/div>
\n

One exacerbation<\/strong> over the last 6 months<\/p>\n<\/div><\/div><\/div><\/div>\n\n\n\n

COPD, chronic obstructive pulmonary disease; FEV1<\/sub>, forced expiratory volume in one second; ICS, inhaled corticosteroids; LABA, long-acting beta2<\/sub>-agonist; LAMA, long-acting muscarinic antagonist.<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n<\/div><\/div><\/div>\n\n\n\n
\n
\n
\n

Jackie,<\/strong> age 65<\/h2><\/div>\n\n\n\n
<\/div>\n\n\n\n

Jackie manages the front desk at a small dental office, but she\u2019s concerned she won\u2019t be able to fulfill her duties much longer. Lately, her COPD symptoms,<\/strong> including dyspnea<\/strong> and chronic productive cough,<\/strong> have kept her from being able to check-in patients or answer phone calls.1<\/sup><\/p>\n\n\n\n

<\/div>\n\n\n\n
\"\"\/<\/picture><\/figure><\/div>
\n

Currently on LABA + LAMA<\/strong> therapy<\/p>\n<\/div><\/div><\/div><\/div>\n\n\n\n

\"\"\/<\/picture><\/figure><\/div>
\n

Post-bronchodilator FEV1<\/sub> is 51%<\/strong> of predicted<\/p>\n<\/div><\/div><\/div><\/div>\n\n\n\n

\"\"\/<\/picture><\/figure><\/div>
\n

Baseline eosinophil count is 60 cells\/\u03bcL<\/span><\/strong>2<\/sup><\/p>\n\n\n\n

<\/div>\n\n\n\n

History of recurrent pneumonia2<\/sup><\/p>\n<\/div><\/div><\/div><\/div>\n\n\n\n

\"\"\/<\/picture><\/figure><\/div>
\n

No exacerbations<\/strong> in the past year<\/p>\n<\/div><\/div><\/div><\/div>\n\n\n\n

\"\"\/<\/picture><\/figure><\/div>
\n

Medicare Part B with Supplemental Plan<\/p>\n<\/div><\/div><\/div><\/div>\n\n\n\n

COPD, chronic obstructive pulmonary disease; FEV1<\/sub>, forced expiratory volume in one second; LABA, long-acting beta2<\/sub>-agonist; LAMA, long-acting muscarinic antagonist.<\/p>\n<\/div>\n\n\n\n

\n
<\/div>
\"\"\/<\/picture>

<\/p><\/figcaption>

Actor Portrayal<\/div><\/div><\/figure><\/div>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n<\/div><\/div><\/div>\n\n\n\n
\n
\n
\n
<\/div>
\"\"\/<\/picture>

<\/p><\/figcaption>

Actor Portrayal<\/div><\/div><\/figure><\/div>\n<\/div>\n\n\n\n
\n

Eva,<\/strong> age 66<\/h2><\/div>\n\n\n\n
<\/div>\n\n\n\n

After retiring from her long-time role as an administrative assistant, Eva was hoping to spend more time in her garden. However, despite completing pulmonary rehabilitation, she continues to experience dyspnea<\/strong>, which limits even light tasks.1,2<\/sup><\/p>\n\n\n\n

<\/div>\n\n\n\n
\"\"\/<\/picture><\/figure><\/div>
\n

Currently on LAMA + LABA<\/strong> therapy<\/p>\n<\/div><\/div><\/div><\/div>\n\n\n\n

\"\"\/<\/picture><\/figure><\/div>
\n

Post-bronchodilator FEV1<\/sub> is 45%<\/strong> of predicted2<\/sup><\/p>\n<\/div><\/div><\/div><\/div>\n\n\n\n

\"\"\/<\/picture><\/figure><\/div>
\n

No exacerbations<\/strong> in the past year<\/p>\n<\/div><\/div><\/div><\/div>\n\n\n\n

COPD, chronic obstructive pulmonary disease; FEV1<\/sub>, forced expiratory volume in one second; LABA, long-acting beta2<\/sub>-agonist; LAMA, long-acting muscarinic antagonist.<\/p>\n\n\n\n

<\/div>\n<\/div>\n<\/div>\n<\/div><\/div><\/div>\n\n\n\n
\n
<\/div>\n\n\n\n
\n
<\/div>\n\n\n\n
\n

A first-in-class<\/mark> approach<\/mark> that may help improve lung function in adult patients with COPD.1,2<\/sup><\/h2><\/div>\n<\/div>\n\n\n\n
<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
<\/div>\n\n\n\n
\n
<\/div>\n\n\n\n

See the impact<\/mark> of OHTUVAYRE on lung function in clinical studies.<\/h3><\/div>\n\n\n\n
<\/div>\n\n\n\n
\n\n\n
Go to clinical data & efficacy<\/span><\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
<\/div>\n\n\n\n

Take a look at the safety profile of OHTUVAYRE.<\/h3><\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
Go to safety<\/span><\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n<\/div>\n\n\n\n
<\/div>\n<\/div><\/div><\/div>\n\n\n\n
<\/div>\n\n\n\n

COPD, chronic obstructive pulmonary disease; ENHANCE, E<\/strong>nsifentrine as a N<\/strong>ovel inHA<\/strong>led N<\/strong>ebulized C<\/strong>OPD thE<\/strong>rapy; ICS, inhaled corticosteroids; LABA, long-acting beta2<\/sub>-agonist; LAMA, long-acting muscarinic antagonist; MOA, mechanism of action; PDE3, phosphodiesterase 3; PDE4, phosphodiesterase 4.<\/p>\n\n\n\n

<\/div>\n\n\n\n

References<\/h3><\/div>\n\n\n\n
<\/div>\n\n\n\n\n
\n
    \n
  1. Anzueto A, Barjaktarevic IZ, Siler TM, et al. Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE trials). Am J Respir Crit Care Med<\/em>. 2023;208(4):406-416. doi:10.1164\/rccm.202306-0944OC<\/li>\n\n\n\n
  2. Sciurba FC, Christenson SA, Rheault T, Bengtsson T, Rickard K, Barjaktarevic IZ. Effect of dual phosphodiesterase 3 and 4 inhibitor ensifentrine on exacerbation rate and risk in patients with moderate to severe COPD. Chest<\/em>. 2025;167(2):425-435. doi:10.1016\/j.chest.2024.07.168<\/li>\n<\/ol>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    Do not use OHTUVAYRE to treat acute episodes of bronchospasm. Background therapy in ENHANCE-1 and ENHANCE-2 did not include participants on LABA…<\/p>\n","protected":false},"author":605,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_trash_the_other_posts":false,"editor_notices":[],"footnotes":""},"ga4_page_audience":[8],"ga4_page_birn_id":[],"ga4_page_branding":[25],"ga4_page_businessunit":[30],"ga4_page_campaign":[],"ga4_page_content_purpose":[70],"ga4_page_customer_journey_stage":[102],"ga4_page_customer_specialty":[163],"ga4_page_experience":[],"ga4_page_indication":[324],"ga4_page_material_intent":[364],"ga4_page_product":[],"ga4_page_region":[747],"ga4_page_therapeuticarea":[814],"user_role":[],"mhh-area-of-interest":[],"access":[],"user_status":[],"class_list":["post-254","page","type-page","status-publish"],"yoast_head":"\nPatient Profiles: Persistent COPD Symptoms<\/title>\n<meta name=\"description\" content=\"View the profiles of hypothetical patients facing persistent COPD symptoms, including dyspnea and chronic productive cough.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.merckconnect.com\/ohtuvayre\/copd-symptoms-patient-profiles\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Patient Profiles: Persistent COPD Symptoms\" \/>\n<meta property=\"og:description\" content=\"View the profiles of hypothetical patients facing persistent COPD symptoms, including dyspnea and chronic productive cough.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.merckconnect.com\/ohtuvayre\/copd-symptoms-patient-profiles\/\" \/>\n<meta property=\"og:site_name\" content=\"ohtuvayre\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-21T20:08:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-content\/uploads\/sites\/378\/2026\/04\/d8d0ef483739fda8704e33351262fbefeeba0d1a.png?w=1920\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Patient Profiles: Persistent COPD Symptoms","description":"View the profiles of hypothetical patients facing persistent COPD symptoms, including dyspnea and chronic productive cough.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.merckconnect.com\/ohtuvayre\/copd-symptoms-patient-profiles\/","og_locale":"en_US","og_type":"article","og_title":"Patient Profiles: Persistent COPD Symptoms","og_description":"View the profiles of hypothetical patients facing persistent COPD symptoms, including dyspnea and chronic productive cough.","og_url":"https:\/\/www.merckconnect.com\/ohtuvayre\/copd-symptoms-patient-profiles\/","og_site_name":"ohtuvayre","article_modified_time":"2026-08-21T20:08:13+00:00","og_image":[{"url":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-content\/uploads\/sites\/378\/2026\/04\/d8d0ef483739fda8704e33351262fbefeeba0d1a.png?w=1920","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.merckconnect.com\/ohtuvayre\/copd-symptoms-patient-profiles\/","url":"https:\/\/www.merckconnect.com\/ohtuvayre\/copd-symptoms-patient-profiles\/","name":"Patient Profiles: Persistent COPD Symptoms","isPartOf":{"@id":"https:\/\/www.merckconnect.com\/ohtuvayre\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.merckconnect.com\/ohtuvayre\/copd-symptoms-patient-profiles\/#primaryimage"},"image":{"@id":"https:\/\/www.merckconnect.com\/ohtuvayre\/copd-symptoms-patient-profiles\/#primaryimage"},"thumbnailUrl":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-content\/uploads\/sites\/378\/2026\/04\/d8d0ef483739fda8704e33351262fbefeeba0d1a.png?w=1920","datePublished":"2026-04-10T05:02:34+00:00","dateModified":"2026-08-21T20:08:13+00:00","description":"View the profiles of hypothetical patients facing persistent COPD symptoms, including dyspnea and chronic productive cough.","breadcrumb":{"@id":"https:\/\/www.merckconnect.com\/ohtuvayre\/copd-symptoms-patient-profiles\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.merckconnect.com\/ohtuvayre\/copd-symptoms-patient-profiles\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.merckconnect.com\/ohtuvayre\/copd-symptoms-patient-profiles\/#primaryimage","url":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-content\/uploads\/sites\/378\/2026\/04\/d8d0ef483739fda8704e33351262fbefeeba0d1a.png","contentUrl":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-content\/uploads\/sites\/378\/2026\/04\/d8d0ef483739fda8704e33351262fbefeeba0d1a.png","width":2256,"height":324},{"@type":"BreadcrumbList","@id":"https:\/\/www.merckconnect.com\/ohtuvayre\/copd-symptoms-patient-profiles\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.merckconnect.com\/ohtuvayre\/"},{"@type":"ListItem","position":2,"name":"Patient profiles"}]},{"@type":"WebSite","@id":"https:\/\/www.merckconnect.com\/ohtuvayre\/#website","url":"https:\/\/www.merckconnect.com\/ohtuvayre\/","name":"ohtuvayre","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.merckconnect.com\/ohtuvayre\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-json\/wp\/v2\/pages\/254","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-json\/wp\/v2\/users\/605"}],"replies":[{"embeddable":true,"href":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-json\/wp\/v2\/comments?post=254"}],"version-history":[{"count":241,"href":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-json\/wp\/v2\/pages\/254\/revisions"}],"predecessor-version":[{"id":3427,"href":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-json\/wp\/v2\/pages\/254\/revisions\/3427"}],"wp:attachment":[{"href":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-json\/wp\/v2\/media?parent=254"}],"wp:term":[{"taxonomy":"ga4_page_audience","embeddable":true,"href":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-json\/wp\/v2\/ga4_page_audience?post=254"},{"taxonomy":"ga4_page_birn_id","embeddable":true,"href":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-json\/wp\/v2\/ga4_page_birn_id?post=254"},{"taxonomy":"ga4_page_branding","embeddable":true,"href":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-json\/wp\/v2\/ga4_page_branding?post=254"},{"taxonomy":"ga4_page_businessunit","embeddable":true,"href":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-json\/wp\/v2\/ga4_page_businessunit?post=254"},{"taxonomy":"ga4_page_campaign","embeddable":true,"href":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-json\/wp\/v2\/ga4_page_campaign?post=254"},{"taxonomy":"ga4_page_content_purpose","embeddable":true,"href":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-json\/wp\/v2\/ga4_page_content_purpose?post=254"},{"taxonomy":"ga4_page_customer_journey_stage","embeddable":true,"href":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-json\/wp\/v2\/ga4_page_customer_journey_stage?post=254"},{"taxonomy":"ga4_page_customer_specialty","embeddable":true,"href":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-json\/wp\/v2\/ga4_page_customer_specialty?post=254"},{"taxonomy":"ga4_page_experience","embeddable":true,"href":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-json\/wp\/v2\/ga4_page_experience?post=254"},{"taxonomy":"ga4_page_indication","embeddable":true,"href":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-json\/wp\/v2\/ga4_page_indication?post=254"},{"taxonomy":"ga4_page_material_intent","embeddable":true,"href":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-json\/wp\/v2\/ga4_page_material_intent?post=254"},{"taxonomy":"ga4_page_product","embeddable":true,"href":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-json\/wp\/v2\/ga4_page_product?post=254"},{"taxonomy":"ga4_page_region","embeddable":true,"href":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-json\/wp\/v2\/ga4_page_region?post=254"},{"taxonomy":"ga4_page_therapeuticarea","embeddable":true,"href":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-json\/wp\/v2\/ga4_page_therapeuticarea?post=254"},{"taxonomy":"user_role","embeddable":true,"href":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-json\/wp\/v2\/user_role?post=254"},{"taxonomy":"mhh-area-of-interest","embeddable":true,"href":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-json\/wp\/v2\/mhh-area-of-interest?post=254"},{"taxonomy":"access","embeddable":true,"href":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-json\/wp\/v2\/access?post=254"},{"taxonomy":"user_status","embeddable":true,"href":"https:\/\/www.merckconnect.com\/ohtuvayre\/wp-json\/wp\/v2\/user_status?post=254"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}